LD
ABBV icon

Lipe & Dalton’s AbbVie ABBV Stock Holding History

Lipe & Dalton’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62M Sell
18,365
-250
-1% -$53.8K 2.15% 13
2026
Q1 		$4.05M Sell
18,615
-590
-3% -$131K 2.12% 16
2025
Q4 		$4.39M Sell
19,205
-595
-3% -$136K 2.17% 13
2025
Q3 		$4.58M Sell
19,800
-4,585
-19% -$934K 2.27% 10
2025
Q2 		$4.53M Sell
24,385
-450
-2% -$83.6K 2.45% 11
2025
Q1 		$5.2M Sell
24,835
-560
-2% -$109K 2.91% 7
2024
Q4 		$4.51M Sell
25,395
-90
-0.4% -$16.5K 2.39% 13
2024
Q3 		$5.03M Sell
25,485
-100
-0.4% -$18.7K 2.54% 10
2024
Q2 		$4.39M Sell
25,585
-831
-3% -$138K 2.36% 12
2024
Q1 		$4.81M Sell
26,416
-159
-0.6% -$27.4K 2.48% 13
2023
Q4 		$4.12M Sell
26,575
-490
-2% -$71.4K 2.23% 15
2023
Q3 		$4.03M Sell
27,065
-375
-1% -$55.1K 2.43% 13
2023
Q2 		$3.7M Sell
27,440
-12,570
-31% -$1.84M 2.11% 17
2023
Q1 		$6.38M Sell
40,010
-1,499
-4% -$229K 3.65% 4
2022
Q4 		$6.71M Sell
41,509
-773
-2% -$119K 3.86% 2
2022
Q3 		$5.67M Sell
42,282
-248
-0.6% -$35.6K 3.56% 4
2022
Q2 		$6.51M Sell
42,530
-674
-2% -$103K 3.81% 3
2022
Q1 		$7M Sell
43,204
-1,943
-4% -$282K 3.42% 4
2021
Q4 		$6.11M Buy
45,147
+1,251
+3% +$148K 2.89% 10
2021
Q3 		$4.74M Buy
43,896
+3,627
+9% +$414K 2.43% 14
2021
Q2 		$4.54M Buy
40,269
+152
+0.4% +$17.1K 2.36% 16
2021
Q1 		$4.34M Buy
40,117
+542
+1% +$58K 2.41% 15
2020
Q4 		$4.24M Buy
39,575
+97
+0.2% +$9.32K 2.61% 10
2020
Q3 		$3.46M Buy
39,478
+682
+2% +$64.2K 2.4% 14
2020
Q2 		$3.81M Sell
38,796
-503
-1% -$44.3K 2.77% 9
2020
Q1 		$2.99M Buy
39,299
+2,506
+7% +$213K 2.53% 17
2019
Q4 		$3.26M Buy
36,793
+411
+1% +$34.1K 2.16% 20
2019
Q3 		$2.75M Buy
36,382
+26
+0.1% +$1.78K 2.01% 20
2019
Q2 		$2.64M Buy
36,356
+286
+0.8% +$22.5K 1.89% 25
2019
Q1 		$2.91M Buy
36,070
+20,740
+135% +$1.7M 2.14% 18
2018
Q4 		$1.41M Buy
15,330
+2,100
+16% +$185K 1.15% 33
2018
Q3 		$1.25M Buy
13,230
+8,200
+163% +$778K 0.85% 40
2018
Q2 		$466K Hold
5,030
– – 0.34% 45
2018
Q1 		$476K Sell
5,030
-140
-3% -$15.4K 0.34% 47
2017
Q4 		$500K Sell
5,170
-200
-4% -$18.8K 0.35% 42
2017
Q3 		$477K Hold
5,370
– – 0.34% 42
2017
Q2 		$389K Hold
5,370
– – 0.25% 49
2017
Q1 		$350K Sell
5,370
-140
-3% -$8.8K 0.25% 48
2016
Q4 		$345K Hold
5,510
– – 0.25% 50
2016
Q3 		$348K Hold
5,510
– – 0.23% 58
2016
Q2 		$341K Buy
5,510
+2,200
+66% +$134K 0.24% 61
2016
Q1 		$189K Buy
3,310
+200
+6% +$11.1K 0.15% 62
2015
Q4 		$184K Buy
+3,110
New +$179K 0.15% 63
2014
Q4 		– Sell
-3,520
Closed -$203K – 67
2014
Q3 		$203K Buy
+3,520
New +$195K 0.13% 60

Other funds holding ABBV

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Lipe & Dalton's ABBV Position: Q2 2026 in Review

Lipe & Dalton reduced its AbbVie (ABBV) stake by 1.3% in Q2 2026, selling an estimated $53.8K and leaving 18,365 shares worth $4.62M. The position accounts for 2.15% of the portfolio, ranked #13.

Lipe & Dalton first reported a position in ABBV in Q3 2014 and has held it in 44 quarters since. The position peaked at $7M in Q1 2022. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Lipe & Dalton held 18,365 shares of AbbVie worth $4.62M as of Q2 2026.
  • Lipe & Dalton sold 250 AbbVie shares in Q2 2026, an estimated $53.8K.
  • AbbVie made up 2.15% of Lipe & Dalton's portfolio in Q2 2026, its #13 holding.
  • Lipe & Dalton first reported a position in AbbVie in Q3 2014 and has held it in 44 quarters since.
  • Lipe & Dalton's AbbVie position peaked at $7M in Q1 2022.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Lipe & Dalton's 13F filing for Q2 2026, filed 14 Jul 2026.